RxDoctor Payments Data

Samantha Mette

Family · Allendale, MINPI 1205477924

Payments from drug & device makers

$7,042in general payments, 2019–2025

Across 409 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • Novo Nordisk$918
  • Lilly USA, LLC$730
  • AstraZeneca$558
  • Boehringer Ingelheim$371
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$7,042100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,042 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$4,894
Medicare patients
26
Services billed
74

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$35,186
EliquisApixaban22$32,911
JardianceEmpagliflozin23$27,874
TrulicityDulaglutide21$25,346
FarxigaDapagliflozin Propanediol14$20,616
MyrbetriqMirabegron14$15,829
XareltoRivaroxaban18$13,831
Rosuvastatin Calcium118$2,596
Levothyroxine Sodium127$2,500
Omeprazole91$2,390
Duloxetine Hcl50$2,310
Atorvastatin Calcium109$2,032
Lisinopril97$1,398
Bupropion XlBupropion Hcl32$1,118
Metoprolol Succinate43$1,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$730$60,53247 claims
PfizerEliquis$1,027$32,91122 claims
Boehringer IngelheimJardiance$371$27,87423 claims
AstraZenecaFarxiga$558$20,61614 claims
Astellas Pharma US IncMyrbetriq$95$15,82914 claims
Johnson & JohnsonXarelto$15$13,83118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.

Other family in Allendale

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →